Abstract

The term autoimmune pancreatitis (AIP) was first used by Yoshida et al. in 1995 to describe a chronic pancreatitis characterized by autoimmune manifestations on laboratory, histopathological and clinical testing [1]. While initial descriptions of the clinical entity arose primarily in Japan, a growing awareness of the condition has led to reports around the world. The fact that AIP has presented so recently as a new clinical entity in gastroenterology is remarkable, while its protean pancreaticobiliary and systemic presentations foster the disease’s unique position within gastrointestinal pathology.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.